NASDAQ: NMRA

Neumora Therapeutics, Inc. Common Stock

Healthcare | Biotechnology

No licensed closing price on file for NMRA. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

Neumora Therapeutics, Inc. Common Stock (NASDAQ: NMRA) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 16:37 UTC.

What Neumora Therapeutics, Inc. Common Stock does

Neumora is a clinical-stage biopharmaceutical company developing novel therapies designed to cross the blood-brain barrier for treating neuropsychiatric, neurodegenerative, and metabolic disorders. The company's most advanced program, navacaprant, is a once-daily oral medication being studied in Phase 3 trials for major depressive disorder, though its first trial did not meet its primary endpoint.

Summarized from Neumora Therapeutics, Inc. Common Stock’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Charts

Charts are in the appInteractive charts for NMRA are available in Oxford Ledge.
Open NMRA in Oxford Ledge →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity (last 90 days)

Source: SEC EDGAR · Filed 2026-08-21

2026-08-21See RemarksOption exercise67,741$48.8K
2026-08-21See RemarksOption exercise21,055$15.2K
2026-08-21See RemarksOption exercise20,553$14.8K

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q2

Siren, L.L.C.8,497,822$14.45M0.0%
BlackRock, Inc.7,791,869$13.25M+279.3%
SOFTBANK GROUP CORP.6,090,301$10.35M0.0%

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2026-08-14Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2025-02-21Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2025-02-13Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →

Company news

View all →

NMRA INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Neumora Therapeutics, Inc.
globenewswire.com2026-06-15NEG
Fewer than five qualifying stories — full tape in the platform →

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for NMRA and 5,000+ tickers.

Create a free account — keep NMRA

For your agent

GET /api/data?ticker=NMRA

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt